Pfizer, Ranbaxy Can't Pause Lipitor Pay-For-Delay Suit

By Melissa Lipman (October 25, 2012, 7:43 PM EDT) -- A New Jersey judge has refused to halt multidistrict antitrust litigation challenging patent infringement settlements Pfizer Inc. reached over its cholesterol treatment Lipitor, ruling that waiting for the U.S. Supreme Court to take and decide similar suits over pay-for-delay deals would stall the case too long.

U.S. District Judge Peter G. Sheridan on Oct. 19 rejected a request from defendants Pfizer, Ranbaxy Inc. and others to stay the MDL until the Supreme Court decides whether it will review a Third Circuit case the plaintiffs have indicated they plan to rely on to make their case.

The plaintiffs' antitrust claims focus mainly...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!